Efficacy and safety analysis of different dose idarubicin plus cytarabine regimen as induction chemotherapy for young patients with de-novo acute myeloid leukemia

被引：0
|
作者：
张仪 [1 ]
机构：
[1] 1st Affil Hosp,Zhejiang Univ
来源：
China Medical Abstracts(Internal Medicine) | 2016年 / 33卷 / 04期
关键词：
AML; IA; were; Efficacy and safety analysis of different dose idarubicin plus cytarabine regimen as induction chemotherapy for young patients with de-novo acute myeloid leukemia; for; of; with;
D O I：
暂无
中图分类号：
R733.71 [急性白血病];
学科分类号：
100214 ;
摘要：
Objective To compare the efficacy,safety and longterm prognosis between different dose idarubicin(IDA)combined with cytarabine(IA)as induction chemotherapy in newly diagnosed young patients of acute myeloid leukemia(AML).Methods A total of 149 newly diagnosed young AML patients(APL excluded)between January 2009 to July 2014 was enrolled.According to the
引用
收藏
页码：231 / 231
页数：1
相关论文
共 50 条
  • [41] POOR RESPONSE TO INTENSIVE CHEMOTHERAPY IN DE-NOVO ACUTE MYELOID-LEUKEMIA WITH TRILINEAGE MYELODYSPLASIA
    KURIYAMA, K
    TOMONAGA, M
    MATSUO, T
    KOBAYASHI, T
    MIWA, H
    SHIRAKAWA, S
    TANIMOTO, M
    ADACHI, K
    EMI, N
    HIRAOKA, A
    TOMINAGA, N
    IMAI, K
    ASOU, N
    TSUBAKI, K
    TAKAHASHI, I
    MINAMI, S
    YOSHIDA, M
    MURAKAMI, H
    MINATO, K
    OSHIMA, T
    FURUSAWA, S
    OHNO, R
    BRITISH JOURNAL OF HAEMATOLOGY, 1994, 86 (04) : 767 - 773
  • [42] IN ACUTE MYELOID LEUKEMIA, THE USE IN INDUCTION OF STANDARD DOSE CYTARABINE IS ASSOCIATED WITH A BETTER QUALITY OF RESPONSE AS COMPARED TO AN INDUCTION REGIMEN CONTAINING HIGH DOSE CYTARABINE
    Maurillo, L.
    Buccisano, F.
    Spagnoli, A.
    Del Principe, M. I.
    Neri, B.
    Cefalo, M. G.
    De Angelis, G.
    Picardi, A.
    Ditto, C.
    Ammatuna, E.
    Del Poeta, G.
    Arcese, W.
    Lo Coco, F.
    Amadori, S.
    Venditti, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 25 - 26
  • [43] Usefulness of a Medication Instruction Sheet for Patients Receiving Cytarabine and Idarubicin Induction Therapy for Acute Myeloid Leukemia
    Uchida, Mayako
    Mochizuki, Erika
    Ishida, Shigeru
    Ozawa, Nana
    Yonemitsu, Hiroko
    Ochiai, Hideki
    Nakamura, Hanae
    Kawashiri, Takehiro
    Kato, Koji
    Egashira, Nobuaki
    Akashi, Koichi
    Ieiri, Ichiro
    IN VIVO, 2023, 37 (02): : 924 - 932
  • [44] Induction chemotherapy with high-dose cytarabine and mitoxantrone in elderly acute myeloid leukemia (AML) patients.
    Ramanathan, Muthalagu
    Cerny, Jan
    Raffel, Glen
    Walsh, William Vincent
    Woda, Bruce
    Miron, Patricia
    Nath, Rajneesh
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [45] A low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus a daunorubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia: A propensity score analysis
    Minakata, Daisuke
    Fujiwara, Shin-ichiro
    Ito, Shoko
    Mashima, Kiyomi
    Umino, Kento
    Nakano, Hirofumi
    Kawasaki, Yasufumi
    Sugimoto, Miyuki
    Yamasaki, Ryoko
    Yamamoto, Chihiro
    Ashizawa, Masahiro
    Hatano, Kaoru
    Okazuka, Kiyoshi
    Sato, Kazuya
    Oh, Iekuni
    Ohmine, Ken
    Suzuki, Takahiro
    Muroi, Kazuo
    Kanda, Yoshinobu
    LEUKEMIA RESEARCH, 2016, 42 : 82 - 87
  • [46] Assessing Efficacy and Safety of Daunorubicin and Cytarabine Liposomal in Patients with Acute Myeloid Leukemia
    Rogers, Elizabeth
    Hibino, Maho
    Hunt, Rebecca Garcia
    Ellis, Leslie Renee
    Bhave, Rupali
    Howard, Dianna S.
    Lyerly, Susan
    Dralle, Sarah
    Manuel, Megan
    Pardee, Timothy S.
    Powell, Bayard L.
    BLOOD, 2019, 134
  • [47] A Phase II Trial of Sirolimus with Standard Induction Chemotherapy in Patients with De Novo Acute Myeloid Leukemia
    Palmisiano, Neil
    Jeschke, Grace
    Leiby, Benjamin E.
    Alpdogan, Onder
    Carabasi, Matthew
    Filicko-O'Hara, Joanne
    Gaballa, Sameh
    Grosso, Dolores
    Klumpp, Thomas R.
    Outschoorn, Ubaldo Martinez
    Wagner, John L.
    Carroll, Martin
    Porcu, Pierluigi
    Flomenberg, Neal
    Perl, Alexander E.
    Kasner, Margaret
    BLOOD, 2017, 130
  • [48] Remission induction therapy of untreated acute myeloid leukemia using a non-cytarabine-containing regimen of idarubicin, etoposide, and carboplatin
    Bow, EJ
    Gallant, G
    Williams, GJ
    Woloschuk, D
    Shore, TB
    Rubinger, M
    Schacter, BA
    CANCER, 1998, 83 (07) : 1344 - 1354
  • [49] A Phase II Trial of Sirolimus with Standard Induction Chemotherapy in Patients with De Novo Acute Myeloid Leukemia
    Keiffer, Gina
    Palmisiano, Neil
    Jeschke, Grace
    Leiby, Benjamin
    Alpdogan, Onder
    Carabasi, Matthew
    Filicko-O'Hara, Joanne
    Gaballa, Sameh
    Grosso, Dolores
    Klumpp, Thomas
    Martinez, Ubaldo
    Wagner, John
    Carroll, Martin
    Porcu, Pierluigi
    Flomenberg, Neal
    Perl, Alexander
    Kasner, Margaret
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S203 - S204
  • [50] FLAIE (FLUDARABINE, CYTARABINE, IDARUBICIN AND ETOPOSIDE) AS INDUCTION CHEMOTHERAPY OF ADULT ACUTE MYELOID LEUKEMIA. A PILOT STUDY REPORT
    Candoni, A.
    Simeone, E.
    Michelutti, A.
    Damiani, D.
    Russo, D.
    Fanin, R.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 123 - 123
12345